Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0000920148
$329.93
+1.91% · live
Updated
$27.12B market value
From LABCORP HOLDINGS INC.'s FY2025 10-K, filed Feb 24, 2026 · read the filing
LABCORP provides healthcare and runs medical facilities. It took in $13.95B last year, which makes it a large company. Of every dollar it sells, about 6 cents is left as profit.
The financial picture is led by accounting, with profitability, growth and debt worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by 2 insiders, not under a pre-arranged plan.
$722.5K sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Generally healthy, with a few things to watch.
From LABCORP HOLDINGS INC.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Cash
$1.52B → $532.3M
Operating income
$1.09B → $1.38B
Profit
$746.0M → $876.5M
Earnings per share
$8.94 → $10.66
Measured against FY2024, from the 10-K filed Feb 24, 2026
Deteriorated: -65.0%
$1.52B to $532.3MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +27.4%
$1.09B to $1.38BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
+17.5%
How the latest move compares (quote live), and what was published around it
LH rose 1.91% on the latest quote. The average Health Care company tracked here moved +1.61%, and the S&P 500 −1.04%. That is in line with its sector and 3.0 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 9% a year for the next 10 years. Over the last 10 years it grew by about 5% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 6 cents of every dollar of sales as profit, earning $876.5M last year.
Slowly. Sales grew 7.2% last year.
Manageable, but notable. Clearing its debt would take about 3.1 years of cash flow. For every $1 it owes, it owns $1.89 in assets.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 27 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 15% of the cash its operations generated. It has paid in each of the last 4 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $876.5M and generated $1.64B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 24, 2026Filing for FY2025 | FY202410-K · Feb 24, 2026Filing for FY2024 | FY202310-K · Feb 25, 2025Filing for FY2023 | FY202210-K · Feb 25, 2025Filing for FY2022 | FY202110-K · Feb 25, 2025Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $13.95B | $13.01B | $12.16B | $11.86B | $13.14B | +7.2% |
| Cost of revenue | $9.94B | $9.38B | $8.80B | $8.15B | $8.14B | +5.9% |
| Gross profit | $4.01B | $3.62B | $3.36B | $3.71B | $4.99B | +10.7% |
| Gross marginGross profit ÷ revenueWhat is this? | 28.8% | 27.9% | 27.7% | 31.3% | 38.0% | +0.9 pts |
| Selling, general and administrative | $2.22B | $2.23B | $2.02B | $1.76B | $1.69B | −0.6% |
| Operating income | $1.38B | $1.09B | $725.6M | $1.44B | $3.05B | +27.4% |
| Operating marginOperating income ÷ revenueWhat is this? | 9.9% | 8.4% | 6.0% | 12.1% | 23.2% | +1.6 pts |
| Interest expense | $224.1M | $208.3M | $199.6M | $179.8M | $211.8M | +7.6% |
| Net income | $876.5M | $746.0M | $418.0M | $1.28B | $2.38B | +17.5% |
| Net marginNet income ÷ revenueWhat is this? | 6.3% | 5.7% | 3.4% | 10.8% | 18.1% | +0.5 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $10.66 | $8.94 | $4.98 | $14.50 | $25.53 | +19.2% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| LHLABCORP HOLDINGS INC. · this page | 7.0/10 | 8/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Sold on the open market — 3,000 shares at $318.02 ($954.1K)
Holds 6,563 shares after this filing.
Sold on the open market — 4,669 shares at $320.37 ($1.5M)
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Made a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingWrite down why you are following LABCORP HOLDINGS INC., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 89 subsidiaries named in its 10-K. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from LH's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 24, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 7.0 | 8/9 | 10-K, filed Feb 24, 2026 |
| FY2024 | 7.0 | 7/9 | 10-K, filed Feb 25, 2025 |
| FY2023 | 7.0 | 6/9 | 10-K, filed Feb 26, 2024 |
| FY2022 | 7.0 | 5/9 | 10-K, filed Feb 28, 2023 |
| FY2021 | 10.0 | 8/9 | 10-K, filed Feb 25, 2022 |
| FY2020 | 10.0 | 9/9 | 10-K, filed Feb 25, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
8 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
3.39
In the safe zone
For this model, above 2.6 is safe and below 1.1 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.55
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
$746.0M to $876.5MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +19.2%
$8.94 to $10.66Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +7.2%
$13.01B to $13.95BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +10.7%
$3.62B to $4.01BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +1.6 pts
8.4% to 9.9%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +10.0%
$1.10B to $1.21BNotable
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: -1.4%
83.4M to 82.2MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Changed: -11.3%
$489.9M to $434.5MNotable
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 5, 2026 — read it.
Deteriorated: -78.1%
$647.3M to $141.8MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +25.6%
$237.9M to $298.7MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +28.7%
$2.87 to $3.69Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: +15.4%
$5.08B to $5.86BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +5.8%
$3.53B to $3.73BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +6.3%
$1.05B to $1.11BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +14.5%
$394.5M to $451.6MNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +1.3 pts
6.7% to 8.0%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: -2.4%
82.9M to 80.9MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 5, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: -85.5%
$981.1M to $141.8MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +18.6%
$380.8M to $451.6MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +5.5%
$3.54B to $3.73BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +9.7%
$1.01B to $1.11BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +7.5%
$277.8M to $298.7MNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +1.1 pts
28.7% to 29.8%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +1.3 pts
10.8% to 12.1%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +9.4%
$3.38 to $3.69Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: -1.7%
82.3M to 80.9MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
4 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 7% and 12%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 27 analysts covering this company, as of . Their views, not this site's.
Of 27 analysts publishing on this company, 9 say strong buy, 12 say buy and 6 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 3.3% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 25.2x — investors pay $25.2 for each $1 of trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 7.2% |
| 6.3% |
| 30.94x |
| 1.13x |
| CVSCVS HEALTH Corp | 4.7/10 | 8/9 | 7.8% | 0.4% | 67.92x | 2.37x |
|---|
| CICigna Group | 6.0/10 | 7/9 | 11.2% | 2.2% | 13.97x | 2.78x |
|---|
| DGXQUEST DIAGNOSTICS INC | 8.0/10 | 8/9 | 11.8% | 9.0% | 27.22x | 1.26x |
|---|
| DVADAVITA INC. | 4.7/10 | 6/8 | 6.5% | 5.5% | 17.08x | -25.07x |
|---|
| Median of peers | 5.3/10 | — | 9.5% | 3.8% | 22.15x | 1.82x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Holds 102,565 shares after this filing.
Sold on the open market — 924 shares at $306.74 ($283.4K)
Holds 6,956 shares after this filing.
Sold on the open market — 82 shares at $309.22 ($25.4K)
Holds 1,770 shares after this filing.
Exercised stock options — 1,338 shares at $209.25 ($280.0K)
Holds 3,108 shares after this filing.
Sold on the open market — 1,338 shares at $309.23 ($413.8K)
Holds 1,770 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 3,000 shares ($954.4K) on or after .
Shares originally obtained via Restricted Stock Awards.
Filed notice to sell 4,669 shares ($1.5M) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 924 shares ($283.4K) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 234 shares ($67.0K) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 92 shares ($26.3K) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 7,138 shares ($2.0M) on or after .
Shares originally obtained via Stock Option Exercise.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Made a Regulation FD disclosure
Made a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q2 FY2026
Revenue +5.8% · Profit margin +1.3 pts · Cash -78.1% — against Q2 FY2025
Read the filingPublished results
Read the filingMade a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Revenue +5.8% · Operating margin +1.0 pts · Free cash flow turned positive — against Q1 FY2025
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingMade a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingAnnual report for FY2025
Revenue +7.2% · Operating margin +1.6 pts · Cash -65.0% — against FY2024
Read the filingThe first 40 of 89. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-24. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
Yahoo ·
LH vs. DHR: Which Stock Is the Better Value Option?
Yahoo ·
Labcorp Holdings Inc. Declares Cash Dividend of $0.72 Per Share
Fintel ·
Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner
Yahoo ·
How Long Can GeneDx Keep Burning Cash?
Yahoo ·
Natera Partners With TransCode to Advance Colorectal Cancer Trial
Yahoo ·
Labcorp Prepares to Report Q3 Earnings: What's in the Cards?
Yahoo ·
Labcorp Declares Quarterly Dividend
Yahoo ·
Sector Update: Healthcare Stocks Gain Late Afternoon
Yahoo ·
Myriad Genetics stock surges on $210M prenatal unit sale
Yahoo ·
Quest Diagnostics (DGX): Is Rapid Test Growth Translating Into Better Customer Economics?
Yahoo ·
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Benzinga ·
Primary sources and further research